{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:22:33Z","timestamp":1783686153069,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3-50127 , P1-0189"],"award-info":[{"award-number":["J3-50127 , P1-0189"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental paediatric disorders and persists into adulthood, although it is frequently underdiagnosed and underrecognized in adult populations. In this context, the prevalence of pharmacologically treated individuals diagnosed with ADHD represents an important quality indicator for ADHD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To estimate the pooled prevalence of pharmacologically treated individuals with ADHD in different age groups in Europe and worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed\/MEDLINE was conducted to identify relevant articles published up to October 4, 2024. The present systematic review and meta-analysis examined ADHD prevalence using clinically confirmed diagnoses and treatment data from official records. The exclusion criteria included studies that lacked clinical confirmation of ADHD and\/or relied exclusively on parental reports for diagnostic or medication information. The prevalence of pharmacologically treated individuals with ADHD was calculated as a percentage, with a 95% confidence interval (CI). A meta-analysis was performed in R using a random-effects model. Heterogeneity was calculated using I\u00b2. Prediction intervals were additionally computed to reflect the expected range of prevalence in future studies. Risk of bias was assessed for all included studies using a standardized, previously published methodology. The study was prospectively registered in PROSPERO (CRD42020200220) and adhered to the PRISMA guidelines for systematic review and meta-analysis (2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The systematic review identified 13 studies (12 studies included in the meta-analysis) with substantial variation in age-specific reporting. The pooled prevalence of pharmacologically treated ADHD was 73.4% (95% CI: 63.4\u201381.5), with extremely high between-study heterogeneity and wide 95% prediction interval (29.6%\u201394.5%), reflecting substantial variation across settings. The pooled prevalence estimate should be interpreted with caution due to substantial between-study heterogeneity and is not intended for direct clinical inference. Geographic analyses revealed no significant variation across countries. Sex-stratified analyses showed no significant difference between males and females, although point estimates were slightly higher in males.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of pharmacological treatment among individuals with ADHD appears to vary across age groups and settings Overall, findings indicate substantial variation in pharmacological treatment of ADHD by age, with consistently high heterogeneity limiting the precision of pooled estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD42020200220.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1854611","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:00:46Z","timestamp":1783684846000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of pharmacologically treated attention deficit hyperactivity disorder in children, adolescents, and adults: systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Sara","family":"Popit","sequence":"first","affiliation":[{"name":"University of Ljubljana, Faculty of Pharmacy","place":["Ljubljana, Slovenia"]},{"name":"Pomurske Lekarne","place":["Murska Sobota, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spela","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"University of Ljubljana, Faculty of Pharmacy","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Locatelli","sequence":"additional","affiliation":[{"name":"University of Ljubljana, Faculty of Pharmacy","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Stuhec","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Pharmacology, Faculty of Medicine Maribor, University of Maribor","place":["Maribor, Slovenia"]},{"name":"Department of Clinical Pharmacy, Ormoz Psychiatric Hospital","place":["Ormoz, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180355","article-title":"The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials","volume":"12","author":"Catal\u00e1-L\u00f3pez","year":"2017","journal-title":"PloS One"},{"key":"B2","unstructured":"International Classification of Diseases, Eleventh Revision (ICD-11)\n          \n          \n          \n          2019"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2250913","article-title":"The diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults","volume":"23","author":"Dobrosavljevic","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05370-w","article-title":"Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines","volume":"183","author":"Van Vyve","year":"2024","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.07.071","article-title":"The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses","volume":"339","author":"Ayano","year":"2023","journal-title":"J Affect Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1786","article-title":"Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis","volume":"67","author":"Popit","year":"2024","journal-title":"Eur Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","article-title":"The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis","volume":"49","author":"Salari","year":"2023","journal-title":"Ital J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.04009","article-title":"The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis","volume":"11","author":"Song","year":"2021","journal-title":"J Glob Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int J Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-021-01871-x","article-title":"The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)","volume":"32","author":"Coghill","year":"2023","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207338","article-title":"Global trends in ADHD medication use: multiple contexts and rising concerns\u2014A narrative review","volume":"14","author":"Rzeszutek","year":"2025","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1701658","article-title":"ADHD: current concepts and treatments in children and adolescents","volume":"51","author":"Drechsler","year":"2020","journal-title":"Neuropediatrics"},{"key":"B14","unstructured":"Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.Pdf"},{"key":"B15","unstructured":"Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NICE Guideline 87)\n          \n          \n          \n          2018"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018795703","article-title":"Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis","volume":"53","author":"Stuhec","year":"2019","journal-title":"Ann Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0269881113519509","article-title":"Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology","volume":"28","author":"Bolea-Alama\u00f1ac","year":"2014","journal-title":"J Psychopharmacol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101780","article-title":"Attention deficit hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study","volume":"58","author":"Chan","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PloS Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1646618","article-title":"Critical appraisal of studies evaluating prevalence of attention deficit hyperactivity disorder","volume":"16","author":"Tivadar","year":"2025","journal-title":"Front Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/070674370104600307","article-title":"Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates","volume":"46","author":"Brownell","year":"2001","journal-title":"Can J Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-012-0501-1","article-title":"Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study","volume":"47","author":"Chien","year":"2012","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000549","article-title":"Recent updates on treatment patterns in patients with treated attention deficit hyperactivity disorder from a nationwide real-world database in South Korea","volume":"39","author":"Cho","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0111","article-title":"Five-fold increase in national prevalence rates of attention deficit hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention deficit hyperactivity disorder, and other psychiatric disorders: a Danish register-based study","volume":"23","author":"Dalsgaard","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18865\/ed.31.1.67","article-title":"Disparities in ADHD diagnosis and treatment by race\/ethnicity in youth receiving kentucky medicaid in 2017","volume":"31","author":"Davis","year":"2021","journal-title":"Ethn Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1087054714554617","article-title":"Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden","volume":"22","author":"Giacobini","year":"2018","journal-title":"J Atten Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/10870547231177221","article-title":"Epidemiology, treatment patterns, comorbidities, and concomitant medication in patients with ADHD in Sweden: A registry-based study (2018-2021)","volume":"27","author":"Giacobini","year":"2023","journal-title":"J Atten Disord"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300148","article-title":"An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom","volume":"66","author":"Raman","year":"2015","journal-title":"Psychiatr Serv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2016045","article-title":"Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011","volume":"38","author":"Song","year":"2016","journal-title":"Epidemiol Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12289","article-title":"Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea","volume":"10","author":"Song","year":"2018","journal-title":"Asia Pac Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161061","article-title":"Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan","volume":"11","author":"Wang","year":"2016","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796016000500","article-title":"Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011","volume":"26","author":"Wang","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1345\/aph.1K143","article-title":"Utilization of pharmacologic treatment in youths with attention deficit\/hyperactivity disorder in Medicaid database","volume":"42","author":"Winterstein","year":"2008","journal-title":"Ann Pharmacother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1854611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:00:48Z","timestamp":1783684848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1854611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2026.1854611"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1854611","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1854611"}}